Adverse Event Management

Brain Cancer

Breast Cancer

Childhood/AYA Cancer

Disparities in Cancer Care

Drug Safety

Gastrointestinal Cancer

Genetics

Genitourinary Cancer

Gynecologic Cancers

Head and Neck Cancers

Hematology

Immuno-Oncology

Lung Cancer

Myeloproliferative Neoplasms

Nurse Navigation

Prevention

Radiation Oncology

Sarcomas

Skin Cancer/Melanoma

Supportive Care

Survivorship

Alyssa Ridad BSN-RN, OCN; and Amanda McKaig, BSN, RN, OCN, discuss oncology nurse perceptions of medical cannabis.

Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis 

Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.

Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run. 

Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors

Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.
 


Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS

News

FDA News

Latest News

Oncology Drug Crash Course

Media

Insights

Medical World News

Peer Exchange

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Contributors

Webinars

Subscribe

Partners

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Articles

The FDA has approved olaparib for patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.

Olaparib Gains FDA Approval for BRCA+ mCRPC

Patients with heavily pretreated advanced melanoma achieved responses with nivolumab and relatlimab. 

Relatlimab/Nivolumab Shows Clinical Activity in Patients With Heavily Pretreated Advanced Melanoma

Applying weighted blankets for 20 minutes reduced patient anxiety during cancer infusions. 

Weighted Blankets Effectively Reduce Anxiety for Patients Undergoing Cancer Treatment 

The PET diagnostic imaging agent, flotufolastat F 18 injection has been approved by the FDA for the identification of prostate-specific membrane antigen–positive lesions in men with prostate cancer

FDA Approves Radiohybrid PET Diagnostic Agent Posluma for PSMA-Positive Lesions in Prostate Cancer

Myeloproliferative Neoplasms

Latest News

Latest Conference Coverage